The Pneumococcal Vaccine Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pneumococcal Vaccine Market:
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report
According to The Business Research Company’s Pneumococcal Vaccine Global Market Report 2024, The pneumococcal vaccine market size has grown strongly in recent years. It will grow from $8.47 billion in 2023 to $9.04 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to discovery of streptococcus pneumoniae, public health concern, early vaccination efforts, healthcare advancements, vaccine policy changes
The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $11.36 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to evolving pneumococcal strains, continued research and development, immunization priorities, expanded vaccine access, population aging. Major trends in the forecast period include multivalent vaccine development, vaccination in at-risk group, boosting vaccine efficacy, education and awareness campaigns, targeting infant immunization.
The increasing prevalence of pneumococcal contamination is expected to propel the growth of the pneumococcal vaccine market going forward. Pneumococcal contamination refers to any infection caused by bacteria called Streptococcus pneumoniae or pneumococcus, such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body to produce antibodies against pneumococcal bacteria to reduce or destroy disease-carrying bacteria and toxins to protect children, the elderly, and those with weakened immune systems from many types of pneumococcal infections. For instance, in January 2022, according to the Center for Disease Control and Prevention, a US-based agency for public health, Pneumococcal pneumonia causes an estimated 150,000 hospitalizations per year in the United States, accounting for up to 30% of adult community-acquired pneumonia. Therefore, the increasing prevalence of pneumococcal contamination is driving the growth of the pneumococcal vaccine market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp
The pneumococcal vaccine market covered in this report is segmented –
1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products
2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous
3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
4) By End User: Pediatrics, Adults
Major companies operating in the pneumococcal vaccine market are innovating new products to increase their profitability in the market. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company launched V116 vaccine. V116 is intended to target the eight distinct serotypes of Streptococcus pneumoniae that are primarily responsible for adult pneumococcal disease. Compared to other pneumococcal vaccines, V116 has shown better immunogenicity for a variety of serotypes in adult populations, and it has also produced positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, and it is currently in Phase 3 development.
The pneumococcal vaccine market report table of contents includes:
1. Executive Summary
2. Pneumococcal Vaccine Market Characteristics
3. Pneumococcal Vaccine Market Trends And Strategies
4. Pneumococcal Vaccine Market – Macro Economic Scenario
5. Global Pneumococcal Vaccine Market Size and Growth
.
.
.
26. South America Pneumococcal Vaccine Market
27. Brazil Pneumococcal Vaccine Market
28. Middle East Pneumococcal Vaccine Market
29. Africa Pneumococcal Vaccine Market
30. Pneumococcal Vaccine Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Johnson & Johnson
- Merck & Co. Inc
- Novartis International AG
- Sanofi S.A
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
